← All indications
Purpura, Thrombocytopenic, Idiopathic
Thrombocytopenia occurring in the absence of toxic exposure or a disease associated with decreased platelets. It is mediated by immune mechanisms, in most cases IMMUNOGLOBULIN G autoantibodies which attach to platelets and subsequently undergo destruction by macrophages. The disease is seen in acute (affecting children) and chronic (adult) forms.
Drugs by status
Approved for this indication (9)
Phase 4 trials (13)
Phase 3 trials (22)
Phase 2 trials (40)
- thalidomide
- acetylcysteine
- bms-986004
- danazol
- glycyrrhizin
- doxorubicin
- obinutuzumab
- tacrolimus
- aldesleukin
- baricitinib
- terbutaline
- ixazomib
- lgd-4665
- Lusutrombopag
- prtx-100
- sitagliptin
- sirolimus
- ski-o-703
- acetylsalicylic acid
- teriflunomide
- veltuzumab
- nicotinamide
- bifidobacterium bifidum
- upadacitinib
- chickpea
- daratumumab
- symphoglobulin-d
- sodium chloride
- zanubrutinib
- Zetomipzomib
- +10 more
Phase 1 trials (13)
Organizations
Organization Involved with Phase 4 Indications (30)
- CSL Behring
- Octapharma
- Qidong Gaitianli Medicines Co., Ltd
- Sunshine Lake Pharma Co., Ltd.
- Huazhong University of Science and Technology
- Central South University
- Anhui Medical University
- Kunming Medical University
- Mahidol University
- Shanxi Medical University
- University of Bern
- Xinjiang Medical University
- Assiut University
- Nanchang University
- Xiamen University
- Zhejiang Chinese Medical University
- Shandong University
- University of Basel
- Tsinghua University
- University of Vienna
- Jiao Tong University
- Medical University of Vienna
- Tianjin Medical University
- Henan Medical University
- Samodzielny Publiczny Szpital
- Nantong University
- Shandong University of Traditional Chinese Medicine
- China Medical University
- Chinese Academy of Medical Sciences
- The First People's Hospital of Yuhang District
Organization Involved with Phase 3 Indications (107)
- Eisai
- UCB
- Green Cross Corporation
- Bio Products Laboratory
- Roche
- CSL
- Genentech
- Grifols
- Biogen
- Novartis
- Anthera Pharmaceuticals
- Baxalta
- Bayer
- Hamilton Health Sciences Corporation
- Hengrui Therapeutics, Inc.
- INC Research
- Kissei Pharmaceuticals
- Kyowa Hakko Kirin
- SK Plasma Co., Ltd.
- Principia Biopharma, Inc.
- Fundação de Amparo à Pesquisa do Estado de São Paulo
- National Heart, Lung, and Blood Institute (NHLBI)
- University of Pennsylvania
- University of Pittsburgh
- Ain Shams University
- Hebei University
- Pakistan Army
- Baylor University
- Case Western Reserve University
- Cornell University
- +77 more
Organization Involved with Phase 2 Indications (48)
- Swedish Orphan Biovitrum
- Takeda
- Millennium Pharmaceuticals
- Bristol-Myers Squibb
- Immunomedics
- AstraZeneca
- Sanofi
- Sanofi-Aventis
- Shionogi
- Oscotec Inc.
- Parexel
- PhytoHealth Corporation
- Protalex, Inc.
- Symphogen A/S
- Iltoo Pharma
- Fondazione Progetto Ematologia
- National Institutes of Health (NIH)
- Aarhus University
- Changhua Christian Hospital
- University of London
- Etablissement Français du Sang
- Glaser Pediatric Research Network
- Hematology and Oncology Specialists
- Hoosier Cancer Research Network
- Kaohsiung Medical University
- Katholieke Universiteit Leuven
- National Cheng Kung University
- Capital Medical University
- Jinan University
- Azienda Ospedaliera Universitaria S. M. Misericordia
- +18 more
Organization Involved with Phase 1 Indications (7)
Organization Involved with Other Experimental Indications (3)